CEVEC Signs Global License Agreement for Human CAP-T Technology with Life Technologies

CEVEC Pharmaceuticals GmbH, operational since 2004 was founded by a group of internationally renowned scientists and clinicians from the University of Cologne. Based on their experience and their longstanding collaborative work, they had perceived a lack of innovative expression systems for more efficient production of biologics such as recombinant proteins or gene therapy vectors. CEVEC's novel proprietary human CAP® and CAP-T® expression systems are ideal for manufacturing complex and difficult to express biopharmaceutical molecules with authentic human glycosylation patterns. The immortalized cells are derived from primary human amniocytes and meet highest ethical standards. Already adapted to serumfree growth conditions, they can be very efficiently transfected with commercially available transfection reagents and are optimized to grow in a variety of flask/wave formats up to largescale processing in bioreactors. CEVEC offers flexible licensing arrangements for CAP and CAP-T. Additionally, codevelopment opportunities are available for selected complex therapeutic proteins made with the CAP Technology to address attractive target markets.